Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis

OBJECTIVE: Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone, once every 3 weeks (R-CHOP21) is commonly used in non-Hodgkin’s lymphoma (NHL), but accompanied by Pneumocystis carinii pneumonia (PCP) as a fatal treatment complication. This study aims to estimate the specific eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaojia, Huang, Xiaoting, Lin, Shen, Luo, Shaohong, Dong, Liangliang, Lin, Dong, Huang, Yaping, Xie, Chen, Nian, Dongni, Xu, Xiongwei, Weng, Xiuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069585/
https://www.ncbi.nlm.nih.gov/pubmed/36972963
http://dx.doi.org/10.1136/bmjopen-2022-068943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069585/
https://www.ncbi.nlm.nih.gov/pubmed/36972963
http://dx.doi.org/10.1136/bmjopen-2022-068943

Ejemplares similares